非酒精性脂肪性肝炎
医学
纤维化
内科学
胃肠病学
阶段(地层学)
脂肪性肝炎
脂肪肝
随机对照试验
非酒精性脂肪肝
疾病
生物
古生物学
作者
Rohit Loomba,Arun J. Sanyal,Atsushi Nakajima,Brent A. Neuschwander‐Tetri,Zachary Goodman,Stephen A. Harrison,Eric Lawitz,Nadege Gunn,Kento Imajo,Natarajan Ravendhran,Takemi Akahane,Bradly Boone,Masayuki Yamaguchi,Arkendu Chatterjee,Giridhar Tirucherai,Diane E. Shevell,Shuyan Du,Edgar D. Charles,Manal F. Abdelmalek
标识
DOI:10.1016/j.cgh.2023.04.011
摘要
Pegbelfermin is a polyethlene glycol-conjugated analog of human fibroblast growth factor 21, a nonmitogenic hormone that regulates energy metabolism. This phase 2b study evaluated 48-week pegbelfermin treatment in patients with nonalcoholic steatohepatitis (NASH) and stage 3 (bridging) fibrosis.
科研通智能强力驱动
Strongly Powered by AbleSci AI